ZURICH, Nov 30 (Reuters) - Swiss biotech company Arpida (ARPN.S: Quote, Profile, Research) said on Thursday its superbug drug iclaprim had proved to be as efficient as Pfizer’s (PFE.N: Quote, Profile, Research) rival drug in a late-stage trial, sending Arpida stock up over 14 percent.
